Mifepristone decreases depression-like behavior and modulates neuroendocrine and central hypothalamic-pituitary-adrenocortical axis responsiveness to stress.
Glucocorticoid dyshomeostasis is observed in a proportion of depressed individuals. As a result, glucocorticoid receptor (GR) antagonists are currently being tested as potential anti-depressants. The current study was designed to test the efficacy of mifepristone, a GR antagonist, in mitigating behavioral, neuroendocrine and central nervous system (CNS) responses to an acute stressor. Adult male rats were treated for 5 days with mifepristone (10 mg/kg) and then exposed to the forced swim test (FST). Treatment with mifepristone decreased immobility and increased swimming (but not climbing) behavior in the FST, consistent with anti-depressant action. In addition, mifepristone dampened the ACTH response to FST exposure. In the CNS, mifepristone increased c-Fos expression in all subdivisions of the medial prefrontal cortex (mPFC) and decreased neuronal activity in some subdivisions of the hippocampus including the CA2, CA3, and hilus region of the dentate gyrus in animals exposed to FST. In contrast, mifepristone increased neuronal activity in the ventral subiculum (output region of the hippocampus) and decreased c-Fos expression in the central amygdala (CeA) in animals exposed to FST. These data suggest that anti-depressant efficacy and perhaps HPA dampening properties of RU486 are related to alterations in key limbic circuits mediating CNS stress responses, resulting in enhanced stress inhibition (via the mPFC and ventral subiculum) as well as decreased stress excitation (central amygdala). Overall the data suggest that drugs targeting the glucocorticoid receptor may ameliorate stress dysfunction associated with depressive illness.
Wulsin
Aynara C
AC
Department of Psychiatry, University of Cincinnati, College of Medicine, Cincinnati, OH 45267, USA. aynara.chavez@gmail.com
Herman
James P
JP
Solomon
Matia B
MB
D000324:Adrenocorticotropic Hormone / Q000097:blood; D000679:Amygdala / Q000187:drug effects; D000818:Animals; D003345:Corticosterone / Q000097:blood; D003863:Depression / Q000188:drug therapy*; D006624:Hippocampus / Q000187:drug effects; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects*; D007031:Hypothalamus / Q000187:drug effects; D008032:Limbic System / Q000187:drug effects; D008297:Male; D015735:Mifepristone / Q000627:therapeutic use*; D010913:Pituitary-Adrenal System / Q000187:drug effects*; D017397:Prefrontal Cortex / Q000187:drug effects; D016760:Proto-Oncogene Proteins c-fos / Q000032:analysis; D051381:Rats; D011965:Receptors, Glucocorticoid / Q000037:antagonists & inhibitors*; D013315:Stress, Psychological / Q000188:drug therapy*; D013550:Swimming / Q000502:physiology / Q000523:psychology
D016760:Proto-Oncogene Proteins c-fos; D011965:Receptors, Glucocorticoid; D015735:Mifepristone; D000324:Adrenocorticotropic Hormone; D003345:Corticosterone